ClinicalTrials.gg
RecruitingNCT06464588Updated Jun 26, 2026

A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

A Phase 1 interventional study of Allogeneic Neonatal mesenchymal stromal cells (nMSCs) in Dilated Cardiomyopathy, sponsored by Emory University. Recruiting at 5 sites in United States. Open to participants aged 4 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Emory University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
4 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Cardiomyopathy, Dilated with a site in United States — 14 open to participants now, 20 under way, 2 of them phase 3. Cardiomyopathy, Dilated · United States.

Planned enrollment
22nd of 42
36 · median 37
Started
2025
with 2 others
Phase 1
5 of 64
2 open now
Primary completion
2027-07
later than 5 of 19 live
Registered
54th of 64
by date
Lead sponsor
2 of 64
Emory University

Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, this one is the 22nd largest by planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 5 of the 19 other live ones, and was the 54th registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

14 of the 64 studies in Cardiomyopathy, Dilated with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 4 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Cardiomyopathy, Dilated with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.

Read the detailed description

This study is a single site open label study with 2 phases. The 2 phases will be broken into an adult group Phase 1A with group pediatric group Phase 1B. This study will enroll patients between the ages of 4 years and 30 years old. The investigators will be looking at the safety, feasibility, and maximum tolerated dose of allogeneic neonatal mesenchymal stromal cells (nMSCs) as defined by freedom from CTCAE or Grade 3 AE that is probably or definitely related to the IP throughout the duration of the study.

A minimum of 9 and a maximum of 18 patients will be enrolled into both Phase 1A adult groups and 1B pediatric groups. Phase 1A subjects will receive study products with doses defined by the study group and Phase 1B will begin after all adult subjects have completed Phase 1A infusions, FDA and a DSMC review. Phase 1B subjects will receive study product dosed per body weight in the defined study group.

Allogeneic neonatal mesenchymal stromal cells (nMSCs) will be infused via IV every 30 days for a total of 3 infusions. There will be a baseline visit before allogeneic neonatal mesenchymal stromal cells (nMSCs) therapy is initiated, followed by a phone call 30 days after the last infusion. There will be in person visits at 3-month, 6 months, and 1 year mark. The total duration for each patient will be 14 months.

Labs will be collected at baseline, during nMSC infusions, and at in person follow up visits to assess cardiac function. Any leftover blood samples may be stored for future research by the sponsor of the study. Echocardiograms will be completed at baseline, and 3 month-, 6 month-, and 1-year visits to look at left ventricular ejection fraction and electrocardiograms will be completed to provide measures of cardiac rhythm or rhythm. Other assessments include physical exam, 6-minute walk test, Cardiac MRI, vital signs, PedsQL questionnaire for pediatrics and The Kansas City Cardiomyopathy Questionnaire for adults.

It is expected to recruit 18-36 participants through face-to-face encounters between participants and study staff during clinical encounters at Children's Healthcare of Atlanta, Emory Health care system, and Grady Health, Clinicaltrials.gov registration, and Institutional Review Board approved advertisements to surrounding hospitals with cardiac programs. Patients will also be recruited through MyChart. If identified as eligible to participate, the study team will seek approval by the subjects' primary cardiologist and consent and/or assent with the permission of the parent or legally authorized representative, will occur in person during a baseline visit.

After allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions, patients will not be required to stay overnight for a follow-up visit. There will be financial compensation for each study visit, and patients will be reimbursed for parking.

03

Conditions studied

  • Dilated Cardiomyopathy

Keywords

  • Dilated Cardiomyopathy
  • Neonatal Mesenchymal Cells (nMSCs)
04

Who can participate

Ages eligible
4 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 1A: Age greater than or equal to 16 years and less than 40 years (≥16 years, \<40 years).
  • Phase 1B: Age greater than or equal to 4 years and less than 16 years (≥4 years, \<16 years)
  • Subjects must be able to sign their own consent for Phase 1A of the study.
  • Diagnosis of dilated cardiomyopathy (DCM) defined as

    • Any Congenital Cardiac Malformation with systemic ventricular systolic dysfunction; Idiopathic Cardiomyopathy; Familial/Inherited and/or Genetic Cardiomyopathy; History of Myocarditis; Acquired (Chemotherapy, Iatrogenic, Infection, Rheumatic, Nutritional); Ischemic (e.g. Kawasaki Disease, post-operative); Left ventricular noncompaction; Coronary Artery Disease
    • less than or equal to 45% documented by two-dimensional echocardiogram or cardiac MRI within the prior six months.
    • Left ventricular dilation as defined by echocardiography left ventricular and end-diastolic dimension Z score > +2.0
    • Biventricular physiology with systemic left ventricle
  • Must receive guideline directed heart failure as defined by the American Heart Association, American College of Cardiology, and Heart Failure Society of America 118
  • Have been unresponsive or poorly responsive to at least 3 months of maximum guideline directed treatments.

Exclusion criteria

Exclusion Criteria

  • Listed for heart transplantation (as UNOS status 1A) or hospitalized while waiting for transplant (while on inotropes or with ventricular assist device)
  • Cardiovascular surgery of percutaneous intervention to palliate or correct congenital cardiovascular malformations within 3 months of the screening visit. Patients anticipated to undergo corrective heart surgery during the 12 months after entry into Part 1A/1B.
  • Previous heart transplant recipient
  • Unoperated primary obstructive or severe regurgitant valve (aortic, pulmonary, mitral or tricuspid) disease, or significant systemic ventricular outflow obstruction or aortic arch obstruction anticipated to require surgical or transcatheter intervention within 6 months.
  • Restrictive or hypertrophic cardiomyopathy
  • Cardiogenic shock
  • Currently on extracorporeal membrane oxygenation support
  • Ventricular assist device support
  • Lethal, uncontrollable arrhythmia defined as an arrhythmia resulting in hemodynamic instability requiring need for defibrillation, continuous intravenous anti-arrhythmic medication or mechanical circulatory support
  • Patients with persistent atrial fibrillation requiring specific pharmacotherapy
  • Amyloidosis
  • Ischemic dilated cardiomyopathy
  • Clinical history of malignant neoplasm within 5 years (with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma)
  • Serious neurologic disorder including loss of vision, stroke, or paralysis
  • High-grade pulmonary embolism requiring interventional catheter procedure or pulmonary hypertension requiring use of pulmonary vasodilators including phosphodiesterase inhibitor or nitric oxide
  • High-grade renal failure [\<45] mL/min/1.73 m2 - serum potassium >5.3 mmol/L
  • Multiple organ failure
  • Non-cardiac condition that limits life span for \<1 year
  • Uncontrolled diabetes ( >9%) at screening
  • Active infection (including endocarditis) requiring pharmacotherapy
  • Sepsis
  • Active hemorrhagic disease (e.g., gastrointestinal bleeding, injury)
  • History of cardiac transplantation
  • Immune system-altering medications, or therapy at the time of enrolment or within the prior 12 weeks
  • Dystrophin-associated cardiomyopathy confirmed by standard cardiomyopathy panel testing
  • Confirmed myocarditis at time of screening
  • Elevated LFTs greater than 2 times at time of consent
  • Elevated WBC greater than upper limit of normal as defined by local lab at time of consent
  • Presence of HLA antibodies specific for therapeutic study product
  • History of noncompliance, alcohol abuse, recreational drug use, or incarceration within the last year
  • Currently pregnant or breastfeeding
  • Unsafe/unfeasible to enroll due to PI/designee discretion
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Adult Cohort

    Adults (≥16 years to \<40 years) will be enrolled into all dose levels (as tolerated) of Phase 1A. Open label nMSCs will be administered intravenously in the following defined dose groups. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels: * Dose level 1: 5.0x107 nMSCs at 0, 15 and 30 days * Dose level 2: 1.0.x108 nMSCs at 0, 15 and 30 days * Dose level 3: 2.5x108 nMSCs at 0, 15 and 30 days Dose escalation will follow 3+3 study design parameters. The treatment between the first and second patients of each dose level will be staggered at least one month after the first patient's first infusion within each dose level. The next dosing group will be initiated at least one month after the last subject in a particular dose level has received the last dose treatment. Once MTD has been determined, 3 additional patients will be enrolled to ensure a total of 6 patients are enrolled in MTD level for confirmation.

    Biological: Allogeneic Neonatal mesenchymal stromal cells (nMSCs)

  • Experimental
    Pediatric Cohort

    Pediatric participants (4 to ≤16 years) will be enrolled as determined in Phase 1B(3+3 study design; open label). nMSCs will be administered intravenously (IV) in the following defined dose groups. The rate of infusion will be approx. 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels: * Dose Level 1: 0.7x106 nMSCs/kg * Dose Level 2: 1.43x106 nMSCs/kg * Dose Level 3: 2.85x106 nMSCs/kg Dose escalation will follow 3+3 study design parameters. Treatment between 1st and 2nd patients of each dose level will be staggered at least 1 month after the 1st patient's first infusion within each dose level. The next dosing group will be initiated one month after the last subject in a particular dose level has received the last dose treatment. Once MTD has been determined, 3 additional patients will be enrolled to ensure a total of 6 patients are enrolled in MTD level for confirmation. Following IV delivery of nMSCs, patients will be followed at 3m, 6m and 1yr.

    Biological: Allogeneic Neonatal mesenchymal stromal cells (nMSCs)

Interventions

  • BiologicalAllogeneic Neonatal mesenchymal stromal cells (nMSCs)

    nMSCs will be administered intravenously in the predefined dose per each group. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels.

    Also known as: nMSCs infusions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with freedom from any Common Toxicity Criteria for Adverse Events (CTCAE) Grade 3 or greater

    Proportion of participants with freedom from any Common Toxicity Criteria for Adverse Events (CTCAE) Grade 3 or greater AE that is probably or related to the IP throughout the duration of the study will be recorded. Results can vary from 0 to 100% and higher proportion correlates with better outcome. TCAE Grade 3 is defined as severe or medically significant not immediately life-threatening; hospitalization or prolongation of hospitalization. Grade 4 and 5 AEs include composite of: death, life-threatening events, initial or prolonged hospitalization, disability of permanent damage and congenital anomaly/birth defects.

    Time frame: End of study, around 12 months post-intervention

  2. Maximum tolerated dose (MTD) in patients with dilated cardiomyopathy

    If two patients in a dosing group have a related SAE or Dose Limiting Toxicity (DLT), then the previous dosing group will be defined as MTD.

    Time frame: End of study, around 12 months post-intervention

Secondary outcomes

  1. Change of left ventricular ejection fraction (LVEF) from baseline

    Change of left ventricular ejection fraction (LVEF) between baseline, 3-month, 6-month, and 12-month follow-up determined by echocardiography and cardiac MRI.

    Time frame: Baseline, 3-month, 6-month, and 12-month post-intervention

  2. Change in N-terminal pro b-type natriuretic peptide (NT-proBNP) levels from baseline

    N-terminal pro b-type natriuretic peptide (NT-proBNP) levels will be collected on infusion days, and all post infusion follow up visits.

    Time frame: Baseline, 3-month, 6-month, and 12-month post-intervention

  3. Change of 6-minute walk test (6MWT) results

    A 6-minute walk test (6MWT) will be completed at baseline, 3-month, 6-month, and 1-year visits to measure functional status if the participant is developmentally appropriate. Distance in meters will be measured until the participant can either walk 6 minutes, or they become too exhausted.

    Time frame: Baseline, 3-month, 6-month, and 12-months post-intervention

  4. Change in quality-of-life validated survey scores in Peds Quality of Life (QOL) survey

    Change in quality-of-life validated survey scores in Peds Quality of Life (QOL) survey (≥4 years - \< 18 years). Total possible score ranges from 0 to 100 and higher scores indicate better QOL.

    Time frame: Baseline, 3-month, 6-month and 12-month post-intervention

  5. Change in Kansas City Cardiomyopathy Questionnaire

    Change in Kansas City Cardiomyopathy Questionnaire will be recorded (≥18 years - ≤30 years). KCCQ scores are scaled from 0 to 100 and summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent.

    Time frame: Baseline, 3-month, 6-month and 12-month post-intervention

07

Study locations

5 of 5 sites recruiting
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
    Recruiting
    • William Mahle, MD · Contact
    • William Mahle, MD · Principal investigator
  • Hughes Spalding Children's Hospital
    Atlanta, Georgia 30303, United States
    Recruiting
    • William Mahle, MD · Contact
    • William Mahle, MD · Principal investigator
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
    Recruiting
    • William Mahle, MD · Contact
    • William Mahle, MD · Principal investigator
  • Arthur M. Blank Hospital
    Atlanta, Georgia 30329, United States
    Recruiting
    • William Mahle, MD · Contact
    • William Mahle, MD · Principal investigator
  • Scottish Rite Children's Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
    • William Mahle, MD · Contact
    • William Mahle, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification and publication. Data will be shared with Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose, to achieve aims in the approved proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following the publication and then for a minimum of 5 years

Access criteria: Proposals should be directed to mahlew@kidsheart.com and Edwin.horwitz@emory.edu. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 18, 2024
StartActual
Jul 14, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06464588
Lead sponsor
Emory University
Collaborators
The Marcus Foundation
Responsible party
William T. Mahle (Professor, Emory University) — Principal investigator
First posted
Jun 18, 2024
Start date
Jul 14, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

William Mahle, MD
Contact
wmahle@emory.edu
404-256-2593
William Mahle, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion